People · Operator
Named in public records as an officer, director or promoter · active 2014–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Reshape Medical, Inc. | — | Biotechnology | Series B | $75.1M | $436.6M | 2014 |
John Lehmann, M.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Lehmann, M.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Thompson | 1 | 17 |
| Casey Tansey | 1 | 14 |
| Bruce Feuchter | 1 | 12 |
| Robert Grant | 1 | 12 |
| George Wallace | 1 | 8 |
| Jeani Delagardelle | 1 | 8 |
| David Milne | 1 | 7 |
| JAMES ADOX | 1 | 5 |
| Kenneth Charhut | 1 | 4 |
| Michael Mashaal | 1 | 3 |
| Eric Milledge | 1 | 2 |
| Michael Mangano | 1 | 2 |
| Kent Charhut | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.